
Madrigal Pharmaceuticals fell 28.4% from $555.60 to $398.08, behind the S&P 500's +10.2%. Its worst day was Feb 19 (−11.1%), and its low came Nov 3 at $396.32.
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Madrigal Pharmaceuticals shares rose 7.3%, while the S&P 500 rose 1.5%.
+7.3% · S&P 500 +1.5%
Madrigal Pharmaceuticals closed at its highest level of the year, 8.5% above where the year started.
+2.0% · S&P 500 +0.6%
Story events cover the past 12 months · Times ET
Madrigal Pharmaceuticals shares fell 7.6%, while the S&P 500 rose 0.7%.
−7.6% · S&P 500 +0.7%
EPS of $-2.57 missed the $-0.52 estimate on $321.1M revenue (est. $313.0M).
−11.1%, the year's worst day · S&P 500 −0.3%
Madrigal Pharmaceuticals shares rose 12.3%, while the S&P 500 fell 1.8%.
+12.3%, the year's best day · S&P 500 −1.8%
EPS of $-3.25 beat the $-4.04 estimate on $311.3M revenue (est. $301.0M).
+7.4% · S&P 500 +1.4%
Madrigal Pharmaceuticals shares rose 7.8%, while the S&P 500 fell 0.7%.
+7.8% · S&P 500 −0.7%
EPS of $-1.99 beat the $-2.32 estimate on $364.3M revenue (est. $349.6M).
−9.8% · S&P 500 +1.7%
EPS of $1.83 beat the $-1.09 estimate on $431.3M revenue (est. $404.1M).
−8.1% · S&P 500 +0.3%
Where it ended: a close of $398.08 on Nov 18, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $1.53, revenue est. $475.8M).
Nothing in the past 12 months.
All MDGL dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MDGL and SPY from Benzinga historical bars. Not investment advice.